Showing results (11-20 of 385) with videos related to
Sort By:
Pageof 39
Rheumatology (Oxford, England)|August 11, 2006
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysisS I Nihtyanova, G M Brough, C M Black, et al.British Journal of Rheumatology|March 6, 1998
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosisC C Bunn, C P Denton, X Shi-Wen, et al.The Journal of Rheumatology|April 1, 1996
Scleroderma fibroblast phenotype is modulated by endothelial cell co-cultureC P Denton, S Xu, K I Welsh, et al.Annals of the Rheumatic Diseases|July 3, 2007
Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?M T Carulli, C Handler, J G Coghlan, et al.Rheumatology (Oxford, England)|September 15, 2005
Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin scoreM Dziadzio, R E Smith, D J Abraham, et al.Journal of Cardiovascular Pharmacology|May 22, 1998
Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblastsS W Xu, C P Denton, M R Dashwood, et al.Clinical and Experimental Dermatology|November 18, 2003
Etanercept-induced systemic lupus erythematosusV J Swale, C M Perrett, C P Denton, et al.Journal of Cardiovascular Pharmacology|May 22, 1998
Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblastsS Xu, C P Denton, A Holmes, et al.Arthritis and Rheumatism|January 1, 2000
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialM Dziadzio, C P Denton, R Smith, et al.Rheumatology (Oxford, England)|May 6, 2003
A cross-sectional comparison of three self-reported functional indices in sclerodermaA E Smyth, A J MacGregor, D Mukerjee, et al.Pageof 39